Lallemand Publishes New Pre-Clinical Findings on the Modes of action of Probiotics in Sleep-Disrupted Conditions
Montreal, Canada, December 2, 2024 — The Rosell® Institute for Microbiome and Probiotics (RIMAP) by Lallemand has released a new pre-clinical study on their probiotic formulas Cerebiome® and Lacidofil®. The results of this study, conducted in collaboration with the team of Dr. Nafissa Ismail at the University of Ottawa, emphasize the modes of action of probiotics in the gut-brain axis by modulating sleep patterns, depression-like behaviors, and related biomarkers.
The animal model study, titled “The effect of probiotic supplementation on sleep, depression-like behavior, and central glucose and lactate metabolism in male and female pubertal mice exposed to chronic sleep disruption” (Murack et al., 2024), shows that probiotic supplementation in mice led to improvements in depressive-like behavior in sleep-disrupted conditions. Specifically, the study demonstrates that supplementation with Cerebiome® and Lacidofil® improves sleep architecture, such as Rapid-Eye Movement (REM) or Non-Rapid-Eye Movement sleep duration but also sleep latency in mice. Both formulas tend to modulate biomarkers related to sleep and depressive-like behavior associated with chronic sleep disturbance.
Stéphane Bronner, Translational Research Director at RIMAP, explains: “The nature of the study allows us to confirm previous findings on the modes of action of Cerebiome®, our most documented psychobiotic, on the microbiota-gut-brain axis. This is an innovative study which demonstrated that probiotics can lessen the effects of sleep disruption on depression-like behaviors in mice. The results were linked to biomarker measurements, including elevated levels of serotonin and tryptophan, which are neurotransmitter metabolites associated with depressive-like behaviors and sleep disruption. Finally, this study demonstrated probiotics’ modes of action to modulate sleep architecture even in rested conditions. It emphasizes the variety of mechanisms exerted by probiotics on the microbiota-gut-brain axis.”
These initial results further enrich the documentation available on the mechanistic action of probiotics and the role of the microbiota-gut-brain axis in the fields of sleep and depression-like behavior. Read the full publication here.
About Cerebiome®: Pioneering Psychobiotic. Game-Changing Science.
Lallemand’s flagship formula, Cerebiome®—a combination of L. helveticus Rosell®-52 and B. longum Rosell®-175—is the most documented probiotic in the world and a benchmark in the mental well-being space, cited in over 1,400 publications. Cerebiome® has been shown to help manage occasional psychological stress in humans with self-perceived stress but otherwise healthy. Cerebiome® is a uniquely and extensively documented psychobiotic with eight elucidated mechanisms of action, boasting distinctive health claims and awards in the field of mental health. Research is ongoing, and more clinical findings will be revealed shortly.
About Lacidofil®: The Original Formula for a Resilient Gut Microbiome
Lallemand’s formula Lacidofil®—a combination of L. rhamnosus Rosell®-11 and L. helveticus Rosell®-52—has accumulated 29 clinical studies (14 in children and 15 in adults), including 14 published papers on the microbiome-gut-brain axis and its implications in early-life stress management. Commercially available since 1995, with a pharmacovigilance program confirming safe use, Lacidofil® is marketed in over 20 countries with various registration statuses and approved health claims.
About the Rosell® Institute for Microbiome and Probiotics by Lallemand
At the Rosell® Institute for Microbiome and Probiotics by Lallemand, our mission is to apply leading-edge technologies and innovative scientific approaches to improve human health. We achieve this by understanding the interaction between people and their functional microbiome. The Rosell® Institute operates as one of the research centers within Lallemand Health Solutions, a global leader in the probiotic industry, specializing in bacteria- and yeast-based probiotic supplements for human health, food applications, and nutricosmetics.
For media inquiries, please contact:
Marilou Luneau, Communications Manager, Lallemand Health Solutions
mluneau@lallemand.com
